A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
11actual
Sites
11
Countries
France, Spain, Sweden +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-01 | actual | When the study began enrolling |
| Primary completion | 2026-02-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-23 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Malignant Melanoma
- Melanoma
- Metastatic Melanoma
- Solid Tumors
Intervention
- Drug: PF-08046031
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured through 30 days after the last study treatment; approximately 6 months
Number of participants with laboratory abnormalities
measured through 30days after the last study treatment; approximately 6 months
Number of participants with dose limiting toxicities
measured up to 28 days
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed